Ashwani K Singal1, Sanjaya K Satapathy2, Nancy Reau2, Robert Wong2, Yong-Fang Kuo2. 1. University of South Dakota Sanford School of Medicine and Avera Transplant Institute, Sioux Falls, SD, USA; Division of Hepatology and Sandra Bass Center for Liver Diseases, Northwell Health, Manhasset, NY, USA; Division of Gastroenterology and Hepatology, Rush University Medical Center, Chicago, IL, USA; Division of Gastroenterology and Hepatology, Alameda Health System - Highland Hospital, Oakland, CA, USA; Department of Biostatistics and Preventive Medicine, University of Texas Medical Branch, Galveston, TX, USA. Electronic address: ashwanisingal.com@gmail.com. 2. University of South Dakota Sanford School of Medicine and Avera Transplant Institute, Sioux Falls, SD, USA; Division of Hepatology and Sandra Bass Center for Liver Diseases, Northwell Health, Manhasset, NY, USA; Division of Gastroenterology and Hepatology, Rush University Medical Center, Chicago, IL, USA; Division of Gastroenterology and Hepatology, Alameda Health System - Highland Hospital, Oakland, CA, USA; Department of Biostatistics and Preventive Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Abstract
BACKGROUND AND AIMS: With the availability of direct acting antivirals (DAA) for hepatitis C virus (HCV) infection, alcoholic liver disease (ALD) has evolved as the leading indication for listing and receipt of liver transplantation (LT) followed by non-alcoholic steatohepatitis and HCV infection. However, data are limited on etiology specific trends on listings and need for LT for hepatocellular carcinoma (HCC). METHODS: We analyzed UNOS database to examine etiology specific listings and receipt of LT for patients with and without HCC. Listings and receipt of LT in the pre-DAA (2007-2012) era were compared to the DAA (2013-2018) era. RESULTS: The analysis shows that among patients without HCV, there is a decreasing trend on the proportion of patients listed and transplanted for HCV, with simultaneous increase on listings and LT for NASH and ALD. Specifically for listings and transplants for HCC, the leading etiology remains HCV infection followed by NASH and ALD. The analysis also showed that LT for AH contributes to about 20% of increase in listings and receipt of LT for ALD.
BACKGROUND AND AIMS: With the availability of direct acting antivirals (DAA) for hepatitis C virus (HCV) infection, alcoholic liver disease (ALD) has evolved as the leading indication for listing and receipt of liver transplantation (LT) followed by non-alcoholic steatohepatitis and HCV infection. However, data are limited on etiology specific trends on listings and need for LT for hepatocellular carcinoma (HCC). METHODS: We analyzed UNOS database to examine etiology specific listings and receipt of LT for patients with and without HCC. Listings and receipt of LT in the pre-DAA (2007-2012) era were compared to the DAA (2013-2018) era. RESULTS: The analysis shows that among patients without HCV, there is a decreasing trend on the proportion of patients listed and transplanted for HCV, with simultaneous increase on listings and LT for NASH and ALD. Specifically for listings and transplants for HCC, the leading etiology remains HCV infection followed by NASH and ALD. The analysis also showed that LT for AH contributes to about 20% of increase in listings and receipt of LT for ALD.
Authors: Alberto Ferrarese; Sara Battistella; Giacomo Germani; Francesco Paolo Russo; Marco Senzolo; Martina Gambato; Alessandro Vitale; Umberto Cillo; Patrizia Burra Journal: Medicina (Kaunas) Date: 2022-02-14 Impact factor: 2.430
Authors: Saleh A Alqahtani; Dieter C Broering; Saad A Alghamdi; Khalid I Bzeizi; Noara Alhusseini; Saleh I Alabbad; Ali Albenmousa; Nasreen Alfaris; Faisal Abaalkhail; Waleed K Al-Hamoudi Journal: BMC Gastroenterol Date: 2021-06-01 Impact factor: 3.067